Structure Therapeutics annual diluted eps
Diluted EPSBasic EPS
2022
2023
2024
2025
Structure Therapeutics EPS History: Annual & Quarterly (GPCR)
Structure Therapeutics's diluted EPS was -$0.80 for fiscal 2025.
View full Structure Therapeutics company overviewStructure Therapeutics annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.80 | -$0.80 | -$0.02 | — |
| 2024 | 2024-12-31 | -$0.78 | -$0.78 | $0.03 | — |
| 2023 | 2023-12-31 | -$0.81 | -$0.81 | $4.70 | — |
| 2022 | 2022-12-31 | -$5.51 | -$5.51 | — | — |
Structure Therapeutics quarterly diluted eps
Diluted EPSBasic EPS
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.49 | -$0.49 | -$0.13 | — |
| Q1 2026 | 2026-03-31 | -$0.35 | -$0.35 | -$0.08 | — |
| Q4 2025 | 2025-12-31 | $0.47 | $0.47 | — | — |
| Q3 2025 | 2025-09-30 | -$0.37 | -$0.37 | -$0.17 | — |
| Q2 2025 | 2025-06-30 | -$0.36 | -$0.36 | -$0.18 | — |
| Q1 2025 | 2025-03-31 | -$0.27 | -$0.27 | -$0.08 | — |
| Q3 2024 | 2024-09-30 | -$0.20 | -$0.20 | $0.01 | — |
| Q2 2024 | 2024-06-30 | -$0.18 | -$0.18 | $0.02 | — |
| Q1 2024 | 2024-03-31 | -$0.19 | -$0.19 | $0.06 | — |
| Q3 2023 | 2023-09-30 | -$0.21 | -$0.21 | $1.06 | — |
| Q2 2023 | 2023-06-30 | -$0.20 | -$0.20 | $1.44 | — |
| Q1 2023 | 2023-03-31 | -$0.25 | -$0.25 | $1.19 | — |
| Q3 2022 | 2022-09-30 | -$1.27 | -$1.27 | — | — |
| Q2 2022 | 2022-06-30 | -$1.64 | -$1.64 | — | — |
| Q1 2022 | 2022-03-31 | -$1.44 | -$1.44 | — | — |
Structure Therapeutics diluted eps trends
Between the periods ended 2022-12-31 and 2025-12-31, Structure Therapeutics's diluted eps increased from -$5.51 to -$0.80, a change of $4.71. The latest reported quarter, Q2 2026, shows -$0.49.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Structure Therapeutics source filings ↗Community posts
Structure reports up to 16.2% weight loss in extended obesity study
Structure Therapeutics ($GPCR) reported up to 16.2% average body-weight reduction at 72 weeks in an open-label extension study of aleniglipron, its experimental oral GLP-1 treatment. Participants in the highest-performing group had escalate ...